QuiaPEG Pharmaceuticals Holding AB (publ) (QUIA.ST)
SEK 0.01
(0.0%)
SEK 0.01
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 17.68 Million SEK | -7.55% |
| 2022 | 19.12 Million SEK | 6.99% |
| 2021 | 17.87 Million SEK | -18.53% |
| 2020 | 21.94 Million SEK | 7.25% |
| 2019 | 20.46 Million SEK | 45.14% |
| 2018 | 14.09 Million SEK | 85.57% |
| 2017 | 7.59 Million SEK | 419.63% |
| 2016 | 1.46 Million SEK | -82.14% |
| 2015 | 8.18 Million SEK | 6.91% |
| 2014 | 7.65 Million SEK | -12.76% |
| 2013 | 8.77 Million SEK | -11.39% |
| 2012 | 9.9 Million SEK | 2.35% |
| 2011 | 9.67 Million SEK | 28.36% |
| 2010 | 7.53 Million SEK | -2.46% |
| 2009 | 7.72 Million SEK | -1.33% |
| 2008 | 7.83 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.66 Million SEK | 0.0% |
| 2024 Q1 | 4.66 Million SEK | 17.65% |
| 2023 Q4 | 3.96 Million SEK | 0.0% |
| 2023 Q1 | 4.87 Million SEK | 8.24% |
| 2023 FY | 13.42 Million SEK | -29.8% |
| 2023 Q2 | 4.87 Million SEK | 0.0% |
| 2023 Q3 | 3.96 Million SEK | -18.67% |
| 2022 FY | 19.12 Million SEK | 6.99% |
| 2022 Q1 | 5.21 Million SEK | -3.76% |
| 2022 Q2 | 4.89 Million SEK | -6.13% |
| 2022 Q4 | 4.5 Million SEK | -0.09% |
| 2022 Q3 | 4.5 Million SEK | -7.92% |
| 2021 Q2 | 4.71 Million SEK | 24.92% |
| 2021 FY | 17.87 Million SEK | -18.53% |
| 2021 Q4 | 5.42 Million SEK | 36.69% |
| 2021 Q1 | 3.77 Million SEK | -26.72% |
| 2021 Q3 | 3.96 Million SEK | -15.92% |
| 2020 Q3 | 7.25 Million SEK | 40.51% |
| 2020 Q2 | 5.16 Million SEK | 18.12% |
| 2020 FY | 21.94 Million SEK | 7.25% |
| 2020 Q1 | 4.37 Million SEK | -27.9% |
| 2020 Q4 | 5.15 Million SEK | -28.98% |
| 2019 FY | 20.46 Million SEK | 45.14% |
| 2019 Q2 | 5.07 Million SEK | 78.9% |
| 2019 Q1 | 2.83 Million SEK | -26.98% |
| 2019 Q4 | 6.06 Million SEK | -6.62% |
| 2019 Q3 | 6.49 Million SEK | 28.09% |
| 2018 Q1 | 2.01 Million SEK | -48.75% |
| 2018 FY | 14.09 Million SEK | 85.57% |
| 2018 Q4 | 3.88 Million SEK | 39.35% |
| 2018 Q3 | 2.78 Million SEK | -48.64% |
| 2018 Q2 | 5.42 Million SEK | 169.75% |
| 2017 FY | 7.59 Million SEK | 419.63% |
| 2017 Q2 | 2.15 Million SEK | 364.3% |
| 2017 Q3 | 1.05 Million SEK | -51.32% |
| 2017 Q4 | 3.92 Million SEK | 273.17% |
| 2017 Q1 | 465 Thousand SEK | -94.33% |
| 2016 Q1 | -3.41 Million SEK | -17.92% |
| 2016 FY | 1.46 Million SEK | -82.14% |
| 2016 Q3 | -3.37 Million SEK | -2.92% |
| 2016 Q4 | 8.2 Million SEK | 342.7% |
| 2016 Q2 | -3.28 Million SEK | 3.89% |
| 2015 Q1 | -3.95 Million SEK | -1311.43% |
| 2015 Q2 | -2.67 Million SEK | 32.44% |
| 2015 Q4 | -2.89 Million SEK | 27.59% |
| 2015 FY | 8.18 Million SEK | 6.91% |
| 2015 Q3 | -4 Million SEK | -49.85% |
| 2014 Q1 | - SEK | 100.0% |
| 2014 FY | 7.65 Million SEK | -12.76% |
| 2014 Q4 | -280 Thousand SEK | 91.04% |
| 2014 Q3 | -3.12 Million SEK | 58.39% |
| 2014 Q2 | -7.5 Million SEK | 0.0% |
| 2013 FY | 8.77 Million SEK | -11.39% |
| 2013 Q4 | -8.77 Million SEK | -297.75% |
| 2013 Q1 | - SEK | 100.0% |
| 2013 Q2 | -6.6 Million SEK | 0.0% |
| 2013 Q3 | 4.43 Million SEK | 167.22% |
| 2012 Q3 | -3.25 Million SEK | 0.0% |
| 2012 Q4 | -1.74 Million SEK | 46.42% |
| 2012 FY | 9.9 Million SEK | 2.35% |
| 2011 Q2 | 1.9 Million SEK | 0.0% |
| 2011 FY | 9.67 Million SEK | 28.36% |
| 2010 Q2 | 1.66 Million SEK | 0.0% |
| 2010 FY | 7.53 Million SEK | -2.46% |
| 2009 Q2 | 2.38 Million SEK | 0.0% |
| 2009 FY | 7.72 Million SEK | -1.33% |
| 2008 FY | 7.83 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.832% |
| Camurus AB (publ) | 1.05 Billion SEK | 98.331% |
| Mendus AB (publ) | 129.13 Million SEK | 86.307% |
| Lipum AB (publ) | 37.3 Million SEK | 52.601% |
| NextCell Pharma AB | -576.01 Thousand SEK | 3169.864% |
| Simris Alg AB (publ) | 38.64 Million SEK | 54.239% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 37.574% |
| Active Biotech AB (publ) | 44.8 Million SEK | 60.537% |
| Amniotics AB (publ) | 29.07 Million SEK | 39.175% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -20.678% |
| BioArctic AB (publ) | 89.62 Million SEK | 80.27% |
| Cantargia AB (publ) | 290.01 Million SEK | 93.903% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | 19.237% |
| CombiGene AB (publ) | 44.14 Million SEK | 59.943% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 87.633% |
| Genovis AB (publ.) | 88.19 Million SEK | 79.951% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 84.633% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -143.299% |
| Intervacc AB (publ) | 79.78 Million SEK | 77.837% |
| Kancera AB (publ) | 63.07 Million SEK | 71.966% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -220.402% |
| LIDDS AB (publ) | 27.75 Million SEK | 36.282% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -143.769% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 86.989% |
| OncoZenge AB (publ) | 15.9 Million SEK | -11.179% |
| Saniona AB (publ) | 1.07 Million SEK | -1541.876% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 94.5% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 95.055% |
| Xintela AB (publ) | 57.31 Million SEK | 69.148% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 90.27% |
| Ziccum AB (publ) | 27.87 Million SEK | 36.57% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -7.817% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 94.242% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 58.522% |
| Corline Biomedical AB | 30.16 Million SEK | 41.385% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 69.528% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 78.738% |
| Aptahem AB (publ) | 10.01 Million SEK | -76.601% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 86.872% |
| Fluicell AB (publ) | 28.61 Million SEK | 38.208% |
| Biovica International AB (publ) | 133.72 Million SEK | 86.776% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | 10.647% |
| AcouSort AB (publ) | 25.87 Million SEK | 31.663% |
| Abliva AB (publ) | 27.86 Million SEK | 36.543% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 90.861% |
| 2cureX AB (publ) | 36.51 Million SEK | 51.577% |
| I-Tech AB | 40.14 Million SEK | 55.955% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 97.943% |
| Cyxone AB (publ) | 28.21 Million SEK | 37.325% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 83.832% |
| Biosergen AB | 26.8 Million SEK | 34.041% |
| Nanologica AB (publ) | 69.88 Million SEK | 74.698% |
| SynAct Pharma AB | 224.49 Million SEK | 92.123% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 59.971% |
| BioInvent International AB (publ) | 441.4 Million SEK | 95.994% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 26.18% |
| Alzinova AB (publ) | 36.39 Million SEK | 51.415% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 93.897% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -125.081% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 84.057% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -20.293% |